Xin Lang Cai Jing·2025-05-23 02:24Group 1 - The core viewpoint is that the innovative pharmaceutical sector is experiencing sustained growth, driven by "innovation + internationalization" trends, supported by policies and increasing global competitiveness [2] - The Innovative Pharmaceutical ETF (560900) has shown strong performance, with a 4.06% increase over the past week, and notable gains in constituent stocks such as Zhongsheng Pharmaceutical (10.02%) and Kelun Pharmaceutical (6.09%) [1] - Hengrui Medicine's debut on the Hong Kong stock market saw a significant opening increase of 29.4%, raising approximately HKD 9.9 billion, with plans to allocate 75% for R&D and 15% for expanding production facilities [1] Group 2 - The innovative pharmaceutical industry chain is showing signs of fundamental improvement, with recovery in overseas orders and performance, and domestic demand expected to rebound in 2025 [2] - The medical device sector is also anticipated to improve in 2025, alongside the emergence of AI in healthcare, which is expected to bring new changes to the pharmaceutical industry [2] - Morgan Asset Management is integrating its global technology investment products to help investors capitalize on opportunities in quality technology companies amid a new wave of technological advancements [2][3]